OBJECTIVES: Since survival after postoperative non-small-cell lung cancer (NSCLC) recurrence is extremely poor, the long-term postrecurrence outcomes are not well understood. The purpose of this study was to evaluate the long-term post-recurrence outcomes and clarify who are possibly 'cured' in recent clinical practice. 
INTRODUCTION
Complete surgical resection provides the best possibility of cure for patients with non-small-cell lung cancer (NSCLC). However, 30-75% of these patients eventually develop recurrence even after complete surgical resection, depending on the final pathological stage [1] [2] [3] . Postoperative NSCLC recurrence is usually systemic and considered to be equivalent to Stage IV disease. Postrecurrence survival (PRS) time has been reported to be poor, with a range of 8-14 months [4, 5] . Thus, postoperative NSCLC recurrence has been associated with a poor prognosis, and most previous studies have focused on the short-term clinical course after recurrence. Few studies have attempted to evaluate the clinicopathological features of long-term survivors after postoperative recurrence and their subsequent survival. On the other hand, it has recently been reported that the survival of patients with Stage IV or recurrent NSCLC has improved, possibly due to the introduction of new drugs, including molecular-targeted agents [6, 7] . The purpose of this study was to clarify the prognostic factors for prolonged PRS, the characteristics of the patients who achieved long-term (5 years or longer) survival after postoperative recurrence and their subsequent outcomes.
PATIENTS AND METHODS

Patient selection
Overall, 2273 consecutive patients underwent complete R0 resection and systematic or lobe-specific nodal dissection of pathological (p-) Stage IA-IIIA NSCLC in our institution between January 1993 and December 2006. An R0 resection was defined as both macroscopic and microscopic complete resection. Patients were generally examined at our outpatient clinic at 3-month intervals for the first 2 years and 6-month intervals thereafter. Follow-up evaluation included physical examination, chest roentography, blood tests including pertinent tumour markers and periodic chest computed tomography (CT) scans. Whenever any symptoms or signs of recurrence were observed, further examinations including chest and abdominal CT scans, brain magnetic resonance imaging, bone scintigraphy and integrated positron emission tomography and CT were also performed. We diagnosed recurrence based on compatible physical examination and diagnostic imaging and confirmed it histologically when it was clinically feasible.
During the follow-up until July 2012, a total of 635 (28%) patients were identified as having developed recurrence and were enrolled in this retrospective study. This study was approved by the institutional review board of our institution in 2016, and the need to obtain written informed consent from each patient was waived. We excluded 131 patients without detailed recurrence status or information. We also excluded 163 patients who had lung lesions proven or suspected of metachronous multiple primary lung cancer. The differential diagnosis between second primary lung cancers and intrapulmonary recurrences was determined by experienced pathologists based on the criteria by Martini and Melamed [8] . These were mostly metachronous intrapulmonary nodules with ground-glass attenuation on thin-section CT scans. The characteristics of the remaining subjects in this study (635 patients) are shown in Fig. 1 .
Evaluation of patients with postoperative nonsmall-cell lung cancer recurrence
In this study, we retrospectively reviewed the medical records of patients who developed postoperative recurrence to obtain clinicopathological information at the time of primary tumour resection, at the initial recurrence and at the fifth post-recurrent year. We defined lobectomy or greater lung resection as a standard resection and segmentectomy or wedge resection of the lung as a limited resection. We defined radiotherapy with a dose of 45 Gy or higher, stereotactic body radiotherapy, cerebral stereotactic radiosurgery and surgery with a curative intent as a radical local therapy. The tumours were staged according to the seventh edition of the tumour-node-metastasis classification developed by the Union for International Cancer Control. The epidermal growth factor receptor (EGFR)-tyrosine mutation status was examined in 64 patients who developed recurrence mostly after 2004, when EGFR mutation analysis was introduced in routine clinical practice in Japan.
Characterization of 5-year survivors after postoperative non-small-cell lung cancer recurrence
The clinicopathological features of the 5-year survivors after initial recurrence were compared with those of non-5-year survivors. Also the subsequent outcomes of 5-year survivors were analysed according to their clinical status at 5 years postoperatively. We classified the 5-year survivors into 2 groups: cancer-controlled group and cancer-bearing group, according to the viability of recurrent tumours at the fifth post-recurrent year. The cancer-controlled group included (i) patients who were clinically and radiographically disease-free if they underwent radical local therapy for their recurrence and (ii) those whose complete or partial response status continued without progression at the fifth post-recurrent year if they received chemotherapy for their initial recurrence. The remaining patients whose recurrent lesions were progressing or still being treated by any modality at the fifth post-recurrent year were classified in the cancer-bearing group. Patients who developed additional recurrent lesions after successful management of the initial recurrence were assigned to the cancer-controlled group if these were controlled as described in (i) and (ii).
Statistical analyses
Differences in categorical variables were analysed using Fisher's exact test. All cumulative survival curves were estimated using the Kaplan-Meier method, and the differences between groups were evaluated by the log-rank test. Recurrence-free survival (RFS) was defined as the time from the date of initial surgery until the date of diagnosis of the initial recurrence or death from any cause. PRS was defined as the time from the date of diagnosis of the initial recurrence to the date of death from any cause or the last follow-up. Patients without events were censored at the last follow-up. Second or further recurrence was not calculated as an event in the PRS analysis. Uni-and multivariable analyses were performed to identify prognostic factors associated with PRS among the potential 8 variables (age, gender, surgical procedure, p-Stage at the initial surgery, histology, presence or absence of distant metastasis at the initial recurrence, RFS and EGFR mutation status) using a Cox proportional hazard model. All but EGFR mutation status, which was only examined in 10% (64 of 635) patients, were entered in both univariable and multivariable analyses. All P-values are reported as 2-sided, with analysed statistical significance was set at <0.05. All statistical analyses were performed with R for Windows GUI front-end version 3.0. 
RESULTS
Clinicopathological characteristics of patients with postoperative non-small-cell lung cancer recurrence Table 1 shows the clinicopathological characteristics of all 635 patients with postoperative recurrence. There were 422 (66%) men and 213 (34%) women with a median age at the initial recurrence of 66 years (range, 36-88 years). Adenocarcinoma was the most common histology and found in 449 (71%) patients, followed by squamous cell carcinoma in 135 (21%) patients. The median follow-up period from the initial recurrence was 80 months (range, 61-138 months) when only censored cases were calculated. The median RFS and PRS times were 24 (range, 0-153) and 9 (range, 0-138) months, respectively (Table 1) . Six patients had a zero RFS after radical resection. One patient died in less than a month after surgery. In the other 5 patients, early recurrence in brain and/or bone was detected in 5-29 days after surgery. The overall 3-and 5-year PRS rates were 23% and 13%, respectively (Fig. 2) .
Prognostic factors associated with post-recurrence survival Table 2 shows the results regarding prognostic factors for PRS in univariable and multivariable analyses. In the multivariable analysis, female gender [hazard ratio (HR) = 0.78; 95% confidence interval, 0.65-0.94), adenocarcinoma histology (versus non-adenocarcinoma, HR = 0.77; 0.63-0.93), absence of distant metastases (locoregionalonly initial recurrence, HR = 0.59; 0.49-0.70) and longer RFS (HR = 0.99; 0.98-0.99) were significantly associated with prolonged PRS. Positive activated EGFR mutations favourably affected prolonged PRS in the univariable model (HR = 0.56) but was not enrolled into the multivariable model due to the limited number of patients.
Characteristics of 5-year survivors after postoperative non-small-cell lung cancer recurrence A total of 51 patients achieved 5-year survival after postoperative recurrence. Table 3 compares the clinicopathological characteristics of 5-year and non-5-year survivors after postoperative recurrence. In the 5-year survivors, the incidence of distant metastasis was significantly lower than that in non 5-year survivors (39% vs 59%, P = 0.01). The 5-year survivors also tended to have more non-adenocarcinomas, although this difference was not significant (30% vs 18%, P = 0.08). In summary, the 5-year survivors had more favourable prognostic factors associated with prolonged PRS as described in Table 2 than non-5-year survivors.
The 5-year survivors (n = 51) were classified as 19 (37%) cancer-controlled and 32 (63%) cancer-bearing patients at the fifth post-recurrent year according to the current criteria. Before 2002, when epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were approved in Japan, cancer-bearing patients accounted for 6 of 11 (55%) patients, and this proportion increased to 26 of 40 (65%) after 2002. The initial recurrence sites and treatment in the 2 groups are shown in Table 4 . The cancer-controlled group included patients with initial recurrence in rare sites, such as abdominal wall, but none of them had bony recurrence. However, there was no significant difference in the proportion of distant metastases between the 2 groups (P = 0.77). The proportion of patients who received radical local therapy with a curative intent was significantly higher in the cancercontrolled group than in the cancer-bearing group (89% vs 56%, P = 0.015; Table 4 ). In the cancer-controlled group, 17 of the 19 (89%) patients initially received radical local therapy including surgery and radiotherapy. In contrast, only 18 of the 32 (56%) patients in the cancer-bearing group initially received radical local therapy. On the other hand, 19 of the 32 (59%) patients in the cancer-bearing group received EGFR-TKIs at some point in their post-recurrent course. Two patients received EGFR-TKIs as a first-line treatment for their postoperative recurrence, and the remaining 17 patients received it as a second-line or a later line treatment. Six patients continuously received EGFR-TKIs until their fifth post-recurrent year.
Subsequent survival of 5-year survivors after postoperative non-small-cell lung cancer recurrence
The PRS curves of the 5-year survivors are shown in Fig. 3 , according to the cancer status at the fifth post-recurrent year. Although all the patients achieved 5-year PRS, the subsequent PRS was significantly different between the 2 groups [8-year (96 months) PRS: 94 vs 31%, P = 0.003). In the cancer-bearing group, 18 (56%) of the 32 patients died from lung cancer after the fifth post-recurrent year. In contrast, none of the 19 cancer-controlled group patients died from lung cancer, although 2 patients died of other causes (respiratory failure and subdural haematoma, respectively).
DISCUSSION
In this study, we analysed factors associated with prolonged PRS and clarified the characteristics of long-term (5 years or longer) survivors after postoperative NSCLC recurrence. Factors that were significantly associated with prolonged PRS were gender (female), histology (adenocarcinoma), the initial recurrent site (locoregional-only) and longer RFS, and multivariable Cox analysis showed that these factors are considered to be independent without interaction. Patients with activated EGFR mutations frequently received EGFR-TKIs (71%), and those with activated EGFR mutations tended to have longer PRS in the univariable model. revealed that the absence of symptoms (HR = 0.45), longer disease-free interval (HR = 0.71), the use of neoadjuvant chemotherapy (HR = 0.63), the use of adjuvant radiation (HR = 0.56) and treatment for initial recurrence (surgery alone, chemotherapy and radiation therapy and surgery combined with radiation therapy; HR = 0.2) were favourable prognostic factors for PRS [10] . The current study confirmed that the clinicopathological factors at the time of recurrence significantly affect PRS and are important to consider when estimating the patient's prognosis. In this study, 63% of 5-year survivors actually had a cancerbearing status, i.e. they were being treated or had progressing tumours at the fifth post-recurrent year. Historically, survival in patients with cancer including NSCLC has been evaluated by the outcome at 5 years and the achievement of 5-year survival has usually been considered to indicate that the patient's cancer has been cured [11] [12] [13] . Treatment efficacy for cancer recurrence has been also evaluated at 5 years [14, 15] . Especially, postoperative NSCLC usually represents systemic disease with a very limited reported PRS time of less than 2 years [4, 5] . Therefore, longterm post-recurrent survivors who have overcome the critical period of tumour progression might be considered 'survivors of cancer'. However, the current results showed that long-term (5 years or longer) survival itself did not represent a 'cure' of postoperative NSCLC recurrence. The proportion of patients in the cancer-bearing group increased after EGFR-TKIs were approved in 2002. Among these cancer-bearing 5-year survivors, 59% were treated with molecular-targeted agents (EGFR-TKIs) during their post-recurrence course. The introduction of EGFR-TKIs might partly contribute improved PRS by increasing the proportion of cancer-bearing patients. EGFR-TKIs provide a dramatic clinical response in patients with advanced or recurrent NSCLC harbouring activated EGFR mutations [6] . However, the effect of EGFRTKIs is cytostatic rather than cytotoxic [16] , and almost all of the patients who respond to EGFR-TKI eventually develop disease progression due to acquired drug resistance [17] and eventually die from cancer progression [18] . On the other hand, cancer-controlled 5-year survivors did not show any tumour progression or cancer-related death after the fifth post-recurrent year, and the post-recurrent 8-year survival rate was 94%. The cancer-controlled group received radical local therapy for the initial recurrence more frequently (89%) than the cancerbearing group. Several studies have revealed that surgical resection of a recurrent site, such as brain or adrenal gland, contributed to long-term survival in patients with recurrence [9, [19] [20] [21] [22] [23] [24] . We previously conducted a retrospective analysis of postoperative oligorecurrence of NSCLC and showed that radical local therapy was significantly associated with prolonged PRS [19] . The previous study and our current results suggest that the successful management of limited recurrence suitable for radical local therapy can provide long-term cancer-controlled survival and even a 'cure'. The current study also showed that a 'cancer-controlled' status at the fifth postrecurrent year is suggestive of a subsequent cancer-controlled survival, a so-called 'cure' of recurrence.
Limitations
Several limitations of our study should be addressed. First, this study was a retrospective study and used the database from a single institution. Although all patients underwent whole-body survey to confirm their recurrence, the imaging modalities used were different across the population. Positron emission tomography/positron emission tomography-CT scans were conducted only after 2004. Post-recurrent surveillance was also not consistent, although a general rule was basically applied to all patients. Second, the treatment choices for recurrence were influenced by many factors such as the recurrence location, the patient's performance status and wishes, treatment feasibility and the physician's preference. The current analysis of prognostic factors for prolonged PRS included a selection bias. Therefore, a multicentre prospective study is needed to confirm our current results. However, to our knowledge, this is the first study to analyse the characteristics of long-term (5 year or longer) survivors after the recurrence of NSCLC. Our results should add to the extant knowledge on this problem. Long-term cancer-controlled survival after recurrence may lead to a cure.
CONCLUSION
In conclusion, this study showed that more than half (63%) of the 5-year survivors after postoperative NSCLC recurrence were cancer-bearing patients who were mainly treated with EGFRTKIs, and they subsequently showed deteriorated survival (8-year PRS: 31%). Cancer-controlled patients at the fifth postrecurrent year, who mainly received radical local therapy for their initial recurrence, showed favourable outcomes without subsequent lung cancer-related deaths (8-year PRS: 94%). Patients who are 'cured' from their postoperative NSCLC recurrence are a selected population, and 'cured' population is included in the patients who are 'cancer controlled' at the fifth post-recurrent year.
